drugset / Trial / NCT05359692
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, efficacy, PK and pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Part 2).
Timeline
- Start
- 2023-03-01
- Primary completion
- 2024-04-20
- Completion
- 2025-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RAGIFILIMAB | Monoclonal antibody | — | Intravenous |
| Subject | Retifanlimab | Monoclonal antibody | — | Intravenous |